Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: a look at pharma CEO pay; Pfizer’s CEO gives the inside track on COVID vaccine development; GSK elaborates on its restructuring and strategic plans; and Kite talks about its cell therapy plans under Gilead. 

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 June 2021, including: a look at pharma CEO pay; Pfizer Inc.’s CEO gives the inside track on COVID-19 vaccine development; GlaxoSmithKline plc elaborates on its restructuring and strategic plans; and Kite Pharma, Inc. talks about its cell therapy plans under Gilead Sciences, Inc.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration" - Scrip, 22 Jun, 2021.)

(Also see "How Pfizer Crafted Its Own ‘Operation Warp Speed’ For The COVID-19 Vaccine" - Scrip, 24 Jun, 2021.)

(Also see "‘New GSK’ Still Has Some Convincing To Do" - Scrip, 24 Jun, 2021.)

(Also see "GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities" - Scrip, 23 Jun, 2021.)

(Also see "Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy" - Scrip, 21 Jun, 2021.)

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel